Shenzhen Tiandakang Gene Engineering

Shenzhen Tiandakang Gene Engineering is a Chinese biotechnology company and a wholly-owned subsidiary of Shenzhen Salubris Pharmaceuticals. Established in 1992, the firm specializes in the development and large-scale manufacturing of recombinant protein therapeutics. Its flagship product, Salupro (recombinant human erythropoietin), is a widely used treatment for anemia in patients with chronic kidney disease and those undergoing chemotherapy. Since its acquisition by Salubris in 2007, Tiandakang has served as the primary biologics production base for the group, leveraging its GMP-certified facilities in Shenzhen. The company continues to play a vital role in Salubris's expansion into the biopharmaceutical sector, focusing on high-quality biologics for the Chinese healthcare market.